Fate Therapeutics, Inc.

Juno Therapeutics Gmbh

Jonathan Rosen

Betsy Rezner

Eigen Peralta

Bahram Valamehr

Ryan Bjordahl

Ian Hardy

Daniel D Shoemaker

David Robbins

Lucas James Thompson

Christian Maine

Compounds that either produced a higher proportion or greater absolute number of phenotypically identified nave, stem cell memory, central memory T cells, adaptive NK cells, and type I NKT cells are identified. Compositions and methods for modulating immune cells including T, NK, and NKT cells for adoptive cell therapies with improved efficacy are provided.

Compositions and methods for immune cell modulation in adoptive immunotherapies

Compounds that either produce a higher proportion or greater absolute number of phenotypically identified naive, stem cell memory, central memory T cells, adaptive NK cells, and type I NKT cells are identified. Compositions and methods for modulating immune cells including T, NK, and NKT cells for adoptive cell therapies, such as those providing improvements in one or more therapeutic outcomes, are provided.

Compounds that either produced a higher proportion or greater absolute number of phenotypically identified naive, stem cell memory, central memory T cells, adaptive NK cells, and type I NKT cells are identified. Compositions and methods for modulating immune cells including T, NK, and NKT cells for adoptive cell therapies with improved efficacy are provided.

Growing community of inventors

San Diego, CA, United States of America

Jonathan Rosen